Vivus Inc. wowed analysts and investors on Wednesday with better-than-expected data from its final two Phase III trials of obesity drug Qnexa (phentermine/topiramate CR). (BioWorld Today)

Biogen Idec Inc. is offering $355 million to acquire partner Facet Biotech Corp., escalating the already contentious negotiations between the two companies and laying the groundwork for a deal that analysts predict will eventually get done at a higher price. (BioWorld Today)

PTC Therapeutics Inc. is expected to announce two drug discovery deals on Wednesday, a potential $1.9 billion whopper with Roche AG and an option exercise by Celgene Corp. for which terms were not disclosed. (BioWorld Today)